Sunshine Biopharma Inc (SBFM)

[Babubd]

Sunshine Biopharma makes massive breakthrough to tackle the deadly coronavirus, Brand Voice, 13 October 2020

The outburst of coronavirus has created a lot of fear and the cases are increasing with each passing day. Amidst the situation, there have been a lot of clinical trials to find a vaccine to curb the deadly virus. Sunshine Biopharma Inc. (OTC PINK: SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs recently announced that has screened and subsequently identified a lead compound from its library of Coronavirus protease inhibitors. The screening which identified the lead compound was performed at the University of Georgia, College of Pharmacy under the guidance of Dr Scott Pegan and David Crich.

The team at Sunshine Biopharma was the first company to evaluate the SARS-CoV-2 protein PLpro, the virus that causes COVID-19 and destroys a human’s immune system. The compounds which were screened recently are based on the technology described in Sunshine Biopharma’s recently filed patent application covering small molecules which can be used to treat Coronavirus infections. These compounds, naphthalene-based PLpro inhibitors, are shown to be effective at halting SARS-CoV-2 PLpro activity as well as replication. They offer a potential rapid development path to generating PLpro-targeted therapeutics for use against SARS-CoV-2. The current ongoing pandemic has claimed the lives of more than one million people globally since it first appeared in December 2019.

Currently, there are no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for a library of molecules that were designed to inhibit the coronavirus proteases, thus shutting down the ability of the virus to multiply and cause illness. As part of its land grant tripartite mission, the University of Georgia is committed to creating and applying new knowledge for the public good. UGA’s Center for Drug Discovery, as well as the Colleges of Pharmacy, are excited to be a part of this ground-breaking research related to the discovery of new treatment options for COVID-19.

Moreover, Sunshine Biopharma is also developing its flagship anti-cancer compound called Adva-27a which is meant to destroy multidrug resistant cancer cells, including pancreatic cancer cells, small-cell lung cancer cells, breast cancer cells and uterine sarcoma cells. The mechanism by which Adva-27a is able to destroy cancer cells is through the inhibition of a key cell-cycle enzyme called Topoisomerase II. With thorough research, Sunshine Biopharma is running several clinical trials to curb these life-threatening diseases and the company is looked by the major pharmaceuticals of the world.

(Syndicated press content is neither written, edited or endorsed by ED Times)

https://in.news.yahoo.com/sunshine-biopharma-makes-massive-breakthrough-091629975.html